Actuate Therapeutics Stock price
Is Actuate Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.
Key metrics
Actuate Therapeutics Stock Analysis
Analyst Opinions
9 Analysts have issued a Actuate Therapeutics forecast:
Analyst Opinions
9 Analysts have issued a Actuate Therapeutics forecast:
Don't miss a Thing! We will send you all news about Actuate Therapeutics directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Actuate Therapeutics Stock News
Company Profile
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.
| Head office | United States |
| CEO | Mr. Schmitt |
| Employees | 12 |
| Website | actuatetherapeutics.com |


